Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release

Neuroscience Letters

Volumn 285, Issue 1, 2000, Pages 61-65

  McNaught, Kevin St P ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Astrocyte; Brain derived neurotrophic factor; Complex I; Glial cell line derived neurotrophic factor; Glutathione; Parkinson s disease; Tumour necrosis factor

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; NEWBORN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; ASTROCYTES; CELL LINE; CELLS, CULTURED; CYTOKINES; GLUTATHIONE; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROGLIA; PROSENCEPHALON; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034607961     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00982-4     Document Type: Article

References (20)

1. Altar A.C., Wiegand S.J., Lindsay R.M., Cedarbaum J.M. Neurotrophic factors: towards a restorative therapy of Parkinson's disease. Olanow W.C., Jenner P., Youdim Y. Neurodegeneration and Neuroprotection in Parkinson's Disease. 1996;116-130 Academic Press, London.
2. Appel E., Kolman O., Kazimirsky G., Blumberg P.M., Brodie C. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. NeuroReport. 8:1997;3309-3312.
3. Boka C., Anglade P., Wallach D., Javoy-Agid F., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:1994;151-154.
4. Castaño A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70:1998;1584-1592.
5. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.-P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA. 94:1997;7531-7536.
6. Inoue S., Susukida M., Ikeda K., Murase K., Hayashi K. Dopaminergic transmitter up-regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) synthesis in mouse astrocytes in culture. Biochem. Biophys. Res. Commun. 238:1997;468-472.
7. McGeer E.G., McGeer P.L. Inflammatory cytokines in the CNS. CNS Drugs. 7:1997;214-228.
8. McNaught K.St.P., Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J. Neurochem. 73:1999;2469-2476.
9. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
10. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:1994;147-150.
11. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 270:1999;45-48.
12. Okragly A.J., Haak-Frendscho M. An acid treatment method for the enhanced detection of GDNF in biological samples. Exp. Neurol. 145:1997;592-596.
13. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., Marsden C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697.
14. Schapira A.H.V., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55:1990;2142-2145.
15. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
16. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hayman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion toxicity: involvement of glutathione system. J. Neurochem. 59:1992;99-106.
17. Springer J.E., Mu X., Bergmann L.W., Trojanowski J.Q. Expression of GDNF mRNA in rat and human nervous tissue. Exp. Neurol. 127:1994;167-170.
18. Stromberg I., Bjorklund H., Dahl D., Johnsson G., Sundstrom E., Olson L. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res. Bull. 17:1986;225-236.
19. Thajeb P., Ling Z.D., Potter E.D., Carver P.M. Effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells. Cell Transplant. 6:1997;297-307.
20. Venero J.L., Beck K.D., Hefti F. 6-Hydroxydopamine lesions reduce BDNF mRNA levels in adult rat brain substantia nigra. NeuroReport. 5:1994;429-432.